Details of the Drug

General Information of Drug (ID: DM8VCBE)

Drug Name

Ibuprofen

Synonyms

ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid; Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol;Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid;Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN

Indication

Disease Entry	ICD 11	Status	REF
Dysmenorrhea	GA34.3	Approved	[1]
Fever	MG26	Approved	[1]
Headache	8A80-8A84	Approved	[1]
Osteoarthritis	FA00-FA05	Approved	[1]
Pain	MG30-MG3Z	Approved	[2]
Patent ductus arteriosus	N.A.	Approved	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

206.28

Logarithm of the Partition Coefficient (xlogp)

3.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 70 mgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 20 mg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 85% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The clearance of drug is 3-13 L/h [6]
Elimination: Ibuprofen is rapidly metabolized and eliminated in the urine thus, this via accounts for more than 90% of the administered dose [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.2 - 2 hours [3]
Metabolism: The drug is metabolized via the liver [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 193.9044 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.006% [8]
Vd: The volume of distribution (Vd) of drug is 0.1 L/kg [9]
Water Solubility: The ability of drug to dissolve in water is measured as 0.038 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Drug resistance	Not Available	NAT2	OTBPDQOY	[10]
Ventricular fibrillation	Not Available	MPO	OTOOXLIN	[10]
-----------

Chemical Identifiers

Formula: C13H18O2
IUPAC Name: 2-[4-(2-methylpropyl)phenyl]propanoic acid
Canonical SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
InChI: InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
InChIKey: HEFNNWSXXWATRW-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3672
ChEBI ID: CHEBI:5855
CAS Number: 15687-27-1
DrugBank ID: DB01050
TTD ID: D0R1QE
VARIDT ID: DR00663
INTEDE ID: DR0844
ACDINA ID: D00320

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 1 (CXCR1)	TTMWT8Z	CXCR1_HUMAN	Inhibitor	[11]
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Inhibitor	[11]
Interleukin-8 (IL8)	TTCTE1G	IL8_HUMAN	Inhibitor	[12]
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[13]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Probable small intestine urate exporter (SLC17A4)	DTHE530	S17A4_HUMAN	Substrate	[14]
Monocarboxylate transporter 2 (SLC16A7)	DTLT3UG	MOT2_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[16]
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[17]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[17]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[18]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[19]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[19]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[19]
Acyl-CoA thioesterase 2 (ACOT2)	DEMEPVJ	ACOT2_HUMAN	Substrate	[20]
Alpha-methylacyl-CoA racemase (AMACR)	DEGKWJB	AMACR_HUMAN	Substrate	[21]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4)	OTQK3M9X	ABHD4_HUMAN	Gene/Protein Processing	[22]
1,4-alpha-glucan-branching enzyme (GBE1)	OTK2N05B	GLGB_HUMAN	Gene/Protein Processing	[22]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Gene/Protein Processing	[22]
15-hydroxyprostaglandin dehydrogenase (HPGD)	OTYZI6JB	PGDH_HUMAN	Gene/Protein Processing	[23]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2)	OTLVN68B	AAKB2_HUMAN	Gene/Protein Processing	[22]
A disintegrin and metalloproteinase with thrombospondin motifs 8 (ADAMTS8)	OT2KFY1S	ATS8_HUMAN	Gene/Protein Processing	[24]
Adenylate cyclase type 1 (ADCY1)	OTSLLFZO	ADCY1_HUMAN	Gene/Protein Processing	[22]
Adenylate kinase 4, mitochondrial (AK4)	OTA0T02Q	KAD4_HUMAN	Gene/Protein Processing	[22]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[25]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[25]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Dysmenorrhea

ICD Disease Classification

GA34.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	2.03E-07	1.68	3.86
Monocarboxylate transporter 2 (SLC16A7)	DTP	MCT2	3.70E-02	-5.67E-01	-1.71E+00
Probable small intestine urate exporter (SLC17A4)	DTP	SLC17A4	1.68E-05	-8.87E-01	-4.08E+00
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.51E-01	-1.41E-01	-8.46E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	5.51E-02	1.95E-01	1.20E+00
Alpha-methylacyl-CoA racemase (AMACR)	DME	AMACR	1.15E-01	-1.23E-01	-1.03E+00
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	3.04E-01	-5.14E-02	-1.57E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	3.90E-02	-3.45E-01	-1.49E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ibuprofen (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[26]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Ibuprofen and Glipizide.	Acute diabete complication [5A2Y]	[27]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Ibuprofen caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[28]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Inotersen.	Amyloidosis [5D00]	[28]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Cilostazol.	Arterial occlusive disease [BD40]	[29]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ibuprofen and Budesonide.	Asthma [CA23]	[30]
Ofloxacin	DM0VQN3	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Kanamycin.	Bacterial infection [1A00-1C4Z]	[32]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Streptomycin.	Bacterial infection [1A00-1C4Z]	[32]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[31]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Ibuprofen and ABT-492.	Bacterial infection [1A00-1C4Z]	[31]
Levofloxacin	DMS60RB	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Etidronic acid.	Bone paget disease [FB85]	[33]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[34]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Ibuprofen caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[29]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Iodipamide.	Cholelithiasis [DC11]	[36]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Levomilnacipran.	Chronic pain [MG30]	[37]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Ibuprofen and Regorafenib.	Colorectal cancer [2B91]	[28]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Ibuprofen and Drospirenone.	Contraceptive management [QA21]	[38]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Ibuprofen and Ardeparin.	Coronary thrombosis [BA43]	[39]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Ibuprofen caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[40]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Ibuprofen caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[41]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Ibuprofen caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[42]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Ibuprofen and Danaparoid.	Deep vein thrombosis [BD71]	[39]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Ibuprofen and Rivaroxaban.	Deep vein thrombosis [BD71]	[43]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Sertraline.	Depression [6A70-6A7Z]	[37]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Vilazodone.	Depression [6A70-6A7Z]	[37]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Vortioxetine.	Depression [6A70-6A7Z]	[37]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Milnacipran.	Depression [6A70-6A7Z]	[37]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Desvenlafaxine.	Depression [6A70-6A7Z]	[37]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Clomipramine.	Depression [6A70-6A7Z]	[37]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Cannabidiol.	Epileptic encephalopathy [8A62]	[28]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Tazemetostat.	Follicular lymphoma [2A80]	[29]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Ibuprofen and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[28]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Sulfinpyrazone.	Gout [FA25]	[29]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Ibuprofen caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[44]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[45]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Ibuprofen caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[47]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[48]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[49]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Ibuprofen caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[26]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Idelalisib.	Mature B-cell leukaemia [2A82]	[50]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Ibuprofen and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[51]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Ibuprofen and Ibrutinib.	Mature B-cell lymphoma [2A85]	[52]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Ibuprofen and Ponatinib.	Mature B-cell lymphoma [2A85]	[53]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Ibuprofen caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[28]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Exjade.	Mineral absorption/transport disorder [5C64]	[54]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Ibuprofen and Panobinostat.	Multiple myeloma [2A83]	[26]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ibuprofen and Deflazacort.	Muscular dystrophy [8C70]	[30]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[29]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Ibuprofen and Dasatinib.	Myeloproliferative neoplasm [2A20]	[55]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Ibuprofen and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[56]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Ibuprofen and Prasugrel.	Myocardial infarction [BA41-BA43]	[28]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Sibutramine.	Obesity [5B80-5B81]	[37]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Dexfenfluramine.	Obesity [5B80-5B81]	[37]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Ibuprofen when combined with Polythiazide.	Oedema [MG29]	[57]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Ibuprofen caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[58]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Ibuprofen and MK-4827.	Ovarian cancer [2C73]	[28]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Ibuprofen caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[59]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Epoprostenol.	Pulmonary hypertension [BB01]	[60]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Iloprost.	Pulmonary hypertension [BB01]	[60]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Everolimus.	Renal cell carcinoma [2C90]	[61]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Temsirolimus.	Renal cell carcinoma [2C90]	[61]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ibuprofen and Dexamethasone.	Rheumatoid arthritis [FA20]	[30]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and Leflunomide.	Rheumatoid arthritis [FA20]	[48]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[28]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ibuprofen and Pitolisant.	Somnolence [MG42]	[28]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Caplacizumab.	Thrombocytopenia [3B64]	[29]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Ibuprofen and Apixaban.	Thrombosis [DB61-GB90]	[28]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Cangrelor.	Thrombosis [DB61-GB90]	[29]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Brilinta.	Thrombosis [DB61-GB90]	[28]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Ibuprofen and Cabozantinib.	Thyroid cancer [2D10]	[62]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Ibuprofen and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[27]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Olsalazine.	Ulcerative colitis [DD71]	[63]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Plazomicin.	Urinary tract infection [GC08]	[32]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Ibuprofen and Betrixaban.	Venous thromboembolism [BD72]	[64]
-----------


⏷ Show the Full List of 80 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acesulfame	E00341	36573	Flavoring agent
Allura red AC dye	E00338	33258	Colorant
Aspartame	E00402	134601	Flavoring agent
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Fumaric acid	E00420	444972	Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben	E00149	7456	Antimicrobial preservative
Monoammonium glycyrrhizate	E00352	62074	Emulsifying agent; Flavoring agent
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Propyl gallate	E00075	4947	Antimicrobial preservative; Antioxidant
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sorbitol monooleate	E00497	6436309	Emollient; Emulsifying agent; Surfactant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Succinic acid	E00044	1110	Buffering agent
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Caramel	E00350	61634	Colorant; Flavoring agent
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dextrose monohydrate	E00538	22814120	Binding agent; Diluent; Flavoring agent; Tonicity agent
Eisenoxyd	E00585	56841934	Colorant
Elemental iron	E00280	23925	Other agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Ferrous oxide	E00241	14945	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose	E00634	Not Available	Coating agent
Kaolin	E00586	56841936	Adsorbent; Diluent; Suspending agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Medium-chain triglyceride	E00640	Not Available	Emollient; Lubricant; Surfactant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 2000	E00649	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 300	E00651	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sorbitan monooleate	E00503	9920342	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 67 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ibuprofen 100 mg tablet	100 mg	Chewable Tablet	Oral
Ibuprofen 200 mg tablet	200 mg	Oral Tablet	Oral
Ibuprofen 100 mg tablet	100 mg	Oral Tablet	Oral
Ibuprofen 400 mg tablet	400 mg	Oral Tablet	Oral
Ibuprofen 600 mg tablet	600 mg	Oral Tablet	Oral
Ibuprofen 800 mg tablet	800 mg	Oral Tablet	Oral
Ibuprofen 200 mg capsule	200 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Ibuprofen FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2713).
3	An overview of clinical pharmacology of Ibuprofen. Oman Med J. 2010 Jul;25(3):155-1661. doi: 10.5001/omj.2010.49.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Rainsford KD: Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009 Dec;17(6):275-342. doi: 10.1007/s10787-009-0016-x. Epub 2009 Nov 21.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	Rao P, Knaus EE: Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008 Sep 20;11(2):81s-110s.
10	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
11	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
12	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
13	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
14	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
15	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
16	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
17	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
18	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
19	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20	A study on the chiral inversion of mandelic acid in humans. Org Biomol Chem. 2014 Sep 14;12(34):6737-44.
21	Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009 Dec;17(6):275-342.
22	Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
23	15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys. 2009 Jul 15;487(2):139-45. doi: 10.1016/j.abb.2009.05.017. Epub 2009 Jun 6.
24	Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
25	Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
26	Cerner Multum, Inc. "Australian Product Information.".
27	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
28	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
30	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
31	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
32	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
33	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
34	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
35	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
36	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
37	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
38	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
39	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
40	Cerner Multum, Inc. "Canadian Product Information.".
41	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
42	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
43	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
44	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
45	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
46	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
47	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
48	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
49	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
50	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
51	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
52	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
53	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
54	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
55	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
56	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
57	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
58	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
59	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
60	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
61	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
62	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
63	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
64	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.